2,2'-(4-bromobut-1-ene-1,1-diyl)bis(3-((naphthalen-1-yloxy)methyl)thiophene) | 922185-88-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2,2'-(4-bromobut-1-ene-1,1-diyl)bis(3-((naphthalen-1-yloxy)methyl)thiophene)
• CAS: 922185-88-4
• 化学式: C₃₄H₂₇BrO₂S₂
• 分子量: 611.623
• InChiKey: SFGLETFUMVVRBQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.49
• 重原子数：
  39.0
• 可旋转键数：
  10.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  18.46
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  2,2'-(4-bromobut-1-ene-1,1-diyl)bis(3-((naphthalen-1-yloxy)methyl)thiophene) 在 sodium hydroxide 、 potassium carbonate 、 potassium iodide 作用下， 以 乙醇 、 丙酮 为溶剂， 生成 1-{4,4-Bis-[3-(naphthalen-1-yloxymethyl)-thiophen-2-yl]-but-3-enyl}-piperidine-2-carboxylic acid
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of the N-diarylalkenyl-piperidinecarboxylic acid derivatives as GABA uptake inhibitors (I)

  摘要：

  Twenty novel N-diarylalkenyl-piperidinecarboxylic acid derivatives were synthesized and evaluated as gamma-aminobutyric acid uptake inhibitors. The biological assay showed that (R)-1-[4,4-bis(3-phenoxymethyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic hydrochloride (4e) possessed almost as strong GAT1 inhibitory activity as tiagabine. The synthesis and structure-activity relationships are discussed. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.09.004
• 作为产物：
  描述：

  4-Bromo-1,1-bis-[3-(naphthalen-1-yloxymethyl)-thiophen-2-yl]-butan-1-ol 在 硫酸 作用下， 以 异丙醇 为溶剂， 以73%的产率得到2,2'-(4-bromobut-1-ene-1,1-diyl)bis(3-((naphthalen-1-yloxy)methyl)thiophene)
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of the N-diarylalkenyl-piperidinecarboxylic acid derivatives as GABA uptake inhibitors (I)

  摘要：

  Twenty novel N-diarylalkenyl-piperidinecarboxylic acid derivatives were synthesized and evaluated as gamma-aminobutyric acid uptake inhibitors. The biological assay showed that (R)-1-[4,4-bis(3-phenoxymethyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic hydrochloride (4e) possessed almost as strong GAT1 inhibitory activity as tiagabine. The synthesis and structure-activity relationships are discussed. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.09.004